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Abstract
Nanoparticles are gaining immense popularity in the medical world, specifically in its use in drug delivery systems.The objective of this paper is to study, based on available published literature, how nanoparticles are utilized in drug delivery and
more importantly to identify the potential toxic effects of nanoparticles. Based on textual research, it is clear that there
are benefits to nanoparticle use, but new studies are showing that there are many potential hazards of nanoparticle-like
particles. In order to fully determine the toxicity of the hundreds of types of nanoparticles, a clear method to categorize
these particles is needed and more research using empty nano-carriers needs to be done.
Introduction
The U.S. National Nanotechnology Initiative defines Nanomaterial
as materials that have at least one dimension in the 1-100 nm
range. Despite its size, you can see things with the effects of
nanoparticles all around you. They give the sunset its red color,
allow birds to navigate, and help geckos stick to trees. All around
us, there are nano-sized materials present form volcanoes, forest
fires, viral particles, biogenic magnetite and combustion products (Nano.gov). What has taken the scientific world by storm
in the last few years is not the naturally existing nanoparticles,
but rather, it is the newfound ability to create new materials on
a nanoscale. The term “Nanotechnology” by the material science
standard refers to the creation of these new particles and its
usage. In the physical sciences, nanotechnology is associated
with the quantum behavior of subatomic particles in nanoscale
structures. In the biomedical sciences, nanotechnology is used
in imaging, diagnosing, monitoring diseases, gene delivery, artificial implants, and targeted drug delivery (Nasimi, Haidari 2013).
Engineered nanomaterials are useful, specifically in drug delivery,
because of their large surface area to mass ratio (Oberdorster
2004). When a drug is encapsulated in a nanoparticle, there is
a more accurate delivery to the targeted tissue. Drug permeability will also increase, thereby reducing the dosing frequency.
For instance, an intravenously administered hydrophilic drug has
poor reabsorption after glomerular filtration, often caused by the
rapid renal clearance of the drug; whereas, encapsulating the drug
in a nanoparticle reduces renal clearance and allows for better
absorption. An orally administered drug has to endure enzymatic
degradation in the gastrointestinal tract and a pass through the
liver before it enters systemic circulation. By encapsulating the
drug in a nanoparticle, the exposures to harsh conditions on the
digestive tract are minimized (Kadam, et al 2012).
The key to using nanoparticles in drug delivery systems is ensuring that the drug can be released at the proper time. In that vein,
a biodegradable nanoparticle formulation would be needed, as it
is the intention to transport and release the drug in order to be
effective. However, model studies to the behavior of nanoparticles have largely been conducted with non-degradable particles. Most data concerning the biological behavior and toxicity
of particles comes from studies on inhaled nanoparticles. This is
part of the unintended release of ultrafine or nanoparticles by

combustion-derived processes such as diesel exhaust particles
(Oberdörster, Oberdörster et al 2005). Research has demonstrated that exposure to these combustion derived ultrafine particles/nanoparticles is associated with a wide variety of effects,
including vascular thrombosis, peripheral thrombosis, increased
plasma fibrinogen levels and cardiovascular effects (Radomski,
Jurasz et al 2005; Oberdorster, Oberdörster et al 2005). Since
the size for both ultrafine and nanoparticles (100 nm) is relatively the same, many use both terms as equivalents. Based on the
similarity of character and size between the two, researchers are
speculating that the adverse effects of ultrafine particles, as part
of environmental pollution, may be similar to the negative effects
of engineered nanoparticles.

Methods
The NCBI PubMedCentral database, the Touro College library
Database, Proquest, and Google Scholar were search engines used to find information. The following key words were
searched to obtain research related to this paper: nanotechnology, nanoparticles, nano-medicine, nanotechnology and medical
uses, nanotechnology and drug delivery, toxic effect of nanoparticles, negative effects of engineered nanoparticles, toxicity and
nanoparticles, applications of nanoparticles, and hazards of nanotechnology. Further sources were found by using appropriate
references cited in various journals and reviews.

Nanoparticles and Drug Delivery
Nanoparticles are formed through natural or human facilitated
degeneration of larger structures or by controlled assembly
processes. These procedures occur either in the gas phase, in
a plasma, in a vacuum phase or in the liquid phase (SCENHIR
2006). Naturally occurring nanoparticles are found in the air
in surprisingly high concentrations - approximately 106 to 108
nanoparticles per liter of air depending on conditions. They originate from the oxidation of volatile compounds, diesel and car
engines, and photo-oxidation. The most significant concentration
of particles and smallest particle size are associated with highspeed road traffic, apparently due to the subtle conditions during
concomitant cooling and dilution of the exhaust gases (SCENHIR
2006).Although there are many naturally occurring nanoparticles,
the ones that are man-made and biodegradable are the ones that
are used in drug delivery systems (Oberdorster 2004).
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Preparation of Nanoparticles
Before choosing a method to prepare nanoparticles for use in
drug delivery, many factors have to be taken into account. Some
of these factors are the size of the nanoparticle required, the
inherent properties of the drug (ex. solubility, stability), surface
characteristics and the degree of biodegradability, biocompatibility and toxicity (Mohanraj, Chen 2006). The following are the
three main methods used to prepare nanoparticles for drug
delivery:
Dispersion of preformed polymers: A polymer is dissolved in an
organic solvent, which is also used as the solvent for the hydrophobic drug. This mixture is then emulsified in an aqueous
solution containing a surfactant.After a stable emulsion is formed,
the organic solvent is evaporated. Some of the polymers used in
this method include poly- lactic acid, poly(D, L-glycolide), poly(D,
L-lactide-co-glycolide) and poly(cyanoacrylate) (Mohanraj, Chen
2006).

carboxyl) (Govender, et al 1999). Once the drug is loaded, the
next step is to ensure an opportune release. In general, the release of the drug is dependent on the solubility of the drug, drug
diffusion through the nanoparticle matrix and nanoparticle matrix degradation. (Mohanraj, Chen 2006). Very often, the drug is
released by interactions between intracellular chemicals and the
nanoparticle matrix. For example, the cationic surface of some
nanoparticles allows penetration through the cell membrane
and the drug is then released after the nanoparticle matrix is
triggered by intracellular glutathione. Another example is the reduction of cadmium sulfate or ferric oxide (which are used to cap
silica nanoparticles) by thiols that release the molecules inside
the nanoparticle (Nasimi, Haidari 2013). An alternate mechanism
for release is the use of pH-responsive nanomaterials. A further
achievement in the area of drug release was reached when a
method was developed to use multifunctional super-magnetic
nanoparticles that can be released remotely (Derfus, et al. 2007).

Passing the Blood Brain Barrier (BBB)
Polymerization method: Monomers a polymerized and form
nanoparticles in aqueous solution.The drug is encapsulated either
by dissolving it in the polymerization medium or by absorption
onto the nanoparticles post- polymerization. The nanoparticles
are separated from the suspension by ultra-centrifugation (Reis,
et al 2006).
Coacervation or ionic gelation method: A significant amount of
research has been focused on the preparation of nanoparticles
using hydrophilic, biodegradable polymers such as chitosan, gelatin and sodium alginate. A method was developed by P. Calvo, et
al. for preparing hydrophilic chitosan nanoparticles by ionic gelation. They mixed two aqueous solutions together- one was the
polymer chitosan and the other was the polyanion sodium triphosphate.The positively charged group of the chitosan interacts
with the negatively charged triphosphate to form coacervates
(an aggregate of colloidal droplets held together by electrostatic
attractive forces) with a size in the range of a nanometer (Calvo,
et al 1997).

From several standpoints the brain is a challenging organ for
drug delivery. First, the occurrence of progressive diseases in
the brain will increase with the aging population. Secondly, the
blood brain barrier (BBB) is well known as the best gatekeeper
in the body toward exogenous substances. Generally pharmaceuticals including most small molecules do not cross the BBB.
The BBB is formed by tight junctions between the cerebral endothelial cells, which abolish all aqueous diffusion pathways, and
by biochemical systems consisting of enzymes, which specifically
metabolize many drugs. However, the barrier properties may be
compromised intentionally or unintentionally by allowing the
passage of nanoparticles (Kreuter, et al. 2002). Many studies were
done that show coating of the nanoparticles with the polysorbate (80) surfactants resulted in transport of drugs across the
blood brain barrier (Schroder 1996). It is interesting to note that
studies were first done using engineered nanoparticles to cross
the BBB; however, with increased research it was discovered and
published that natural ultrafine particles can cross the BBB and
cause damage.

Drug Loading and Release

Toxicological Hazards of Nanoparticles

The ideal nanoparticle for drug delivery should have a high
drug loading capacity, thereby reducing the quantity of matrix
materials (Mohanraj, Chen 2006). The two main ways to load
a drug into a nanoparticle is by incorporating it at the time of
nanoparticle production, or absorbing the drug after formation
of the nanoparticles by incubating the nanoparticle carrier with
a concentrated drug solution. The efficiency in loading the drug
is very much dependent on the solubility of the drug in a solid
state into the matrix material or polymer.The solubility is related
to the polymer composition, molecular weight, the drug-polymer
interactions and the type of functional group present (ester or

General concepts
To effectively tap into the potential of Nanotechnology in
Nanomedicine, full attention is needed to focus on safety and
toxicological issues. For pharmaceuticals, precise drug delivery
formulations may be used to increase the so called “therapeutic
ratio” which is the margin between the dose needed for clinical efficacy and the dose that would induce adverse side effects
(toxicity). Also, for these specific formulations, a toxicological
evaluation is needed. The US Food and Drug Administration approval is crucial for clinical applications of nanotechnology, but
considerable problems come into account when it comes to
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approving nanotechnology-based products. The Food and Drug
Administration regulate pharmaceuticals and biological devices
differently, and it is not yet clear how emerging nanotherapeutics
will be evaluated. It is important to have a safety guide particularly in the applications of nanoparticles for drug delivery. In these
applications, particles are brought intentionally into the human
body and environment (Buxton, et al 2003). Opinions started to
divert when toxicologists claimed that new science, methods and
protocols are needed (Nel et al 2006). However, the need for
a safety guide is now underlined by several expert reports and
more importantly by the following concepts:
1) Nanomaterials are made for their unique surface properties
as opposed to the similar properties of bulk materials. Since the
surface is the layer that interacts with the body tissue, and an
essential factor of particle response, these unique properties
need to be investigated from a toxicological perspective. When
nanoparticles are used for their distinctive reactive characteristics, it may be probable that these same characteristics also have
an impact on the toxicity of such particles. Although existing
tests and procedures in drug and device assessment may work
to detect many risks related to the use of these nanoparticles,
it cannot be presumed that these assays will detect all potential
risks. (SCENIHR 2006) The toxicity may differ depending on the
type of particles used, i.e., biological versus non-biological origin.

2) Nanoparticles are recognized as having different physical and
chemical characteristics from micron-sized particles. This may
result in changed body distribution, passage of the blood brain
barrier and triggering of blood coagulation pathways. In view
of these characteristics, specific emphasis should be on testing
and studying the distribution of nanoparticles. What is currently
lacking is a basic comprehension of the biological behavior of
nanoparticles in relation to the distribution in vivo both at the
organ and cellular level.
Using nanoparticles as a drug carrier may reduce the toxicity of
the incorporated drug. In general, research focuses on the toxicity of the entire formulation.The results of the nanoparticles itself
are not described, so differentiation between drug and nanoparticle toxicity cannot be made.There should be a specific emphasis
on the toxicity of the “empty” non-drug loaded particles. This is
especially important when slow or non-degradable particles are
used for drug delivery. (Oberdorster, Maynard, et al. 2005)

Evidence for Nanoparticle Toxicity
The largest database on the toxicity of nanoparticles comes from
the PM10 literature (particulate matter with a size below 10 mm),
where studies on inhalation and the ‘Nanoparticle hypothesis’
have proved to be a powerful drive for research (Oberdörster,
Oberdörster et al 2005). Therefore it is relevant to discuss this

Table 1

Particle type

Description

PM10, PM2.5

Particle mass fraction in ambient air with a mean diameter of 10 or 2.5 μm
respectively. Basis of current standards for ambient particles in Europe and USA

Coarse particles

The mass fraction of PM10, which is bigger than 2.5 μm

Ultrafine particles
(PM0.1)

The fraction of PM10 with a size cut-off at 0.1 μm. Contains primary particles and
agglomerates smaller than 100 nm

PSP

Poorly soluble particles with low specific toxicity. Maybe be fine or ultrafine.
Terminology used in relation to bulk synthetic particles. Examples TiO2, carbon
blacks, Amorphous silica, Iron oxides (Fe2O3), Zinc oxides (ZnO)

CDNP

Combustion derived nanoparticles, such as diesel exhaust particles (DEP)

DEP

Diesel exhaust particles

Various denominations of particles in inhalation toxicology and drug delivery in relation to their source (ambient, bulk, engineered)
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evidence with the expectation that it will shed light on the toxicity of engineered nanoparticles. The adverse health effects of
particulate matter (PM) are measurable as causes of respiratory
disease and deaths as well as hospitalizations and deaths from
respiratory and cardiovascular disease. Many laboratory studies
have been done to investigate the effects of ultrafine and PM particles. It was found that some nanoparticles might have the extra
potential of affecting cardiovascular disease directly. Vascular
function was impaired after inhalation of diesel exhaust particles.
However, data to date is limited and not all studies of nanoparticles have shown significant translocation from lung to the blood.
Understanding clearance kinetics of inhaled ambient air nanoparticles will also be important in understanding the potential for
adverse effects. (Oberdorster, Maynard, et al. 2005)
The current standard in particle toxicology is that ultrafine ambient air particles have the potential of affecting cardiovascular
disease both indirectly via pulmonary inflammation and directly
through particle distribution. Although significant, this property
of redistribution has yet to be demonstrated for nanoparticles
present in real PM10’s. It should be noted that there are several
mechanisms whereby nanoparticles could lead to inflammatory
effects, as is the case for larger particles. These mechanisms are
either based on the large surface area of a particle core or on
soluble components released by the nanoparticles (Schins, et
al. 2004). Several toxicological studies support the argument
that nanoparticles in PM10’s could drive inflammatory effects.
There are a number of components of PM10’s that contribute
to the mass but have little toxicity, including salts such as sulfates, chlorides and ammonium salts and nitrates. In fact, within
PM10’s there are only few components that toxicologists would
identify as likely causes of adverse effects – i.e., particle surfaces,
organics, metals and endotoxins. A large surface area, organics
and metals are all characteristic of combustion–derived particles
and so these have attracted considerable toxicological attention
(Donaldson, et al. 2005).

Effects of Nanoparticle Toxicity
Many physicochemical factors can influence the potential biological
interactions and toxicity of nanoparticles. Therefore, it is important to consider the extent to which the physicochemical properties of nanoparticles have been characterized in any given study.
Without sufficient characterization, it is extremely challenging to
interpret the results of individual studies and virtually impossible
to compare the results of different studies, even in cases where
the same nanoparticle has been investigated. As a result, the ability
to identify parameters that might influence toxicity is hampered.
Although there is not yet a universally accepted standard of parameters that is deemed necessary for nanoparticle characterization, recent reports have highlighted several key physicochemical elements for which it is strongly recommended that data be
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reported (Oberdörster, Maynard, et al. 2005). These limitations
include method of synthesis, size, size distribution, shape, composition, crystal structure, aggregation and agglomeration status,
dissolution, purity, surface area, and other surface characteristics.
Classification of nanoparticles in the context of the experimental
contact media (cell culture media, dosing solution, aerosol, etc.) is
also of substantial importance, as some physicochemical parameters are likely to differ depending on whether they are determined
in the experimental media or in the bulk (i.e., “as received”) state.
Unfortunately, the inclusion of all these parameters in publications
describing nanoparticle toxicity studies appears to be rare.

Nanoparticles in The Lungs
When nanoparticles enter the respiratory system, they are thought
to cause damage that results primarily from lung particle overload.
This is due to the inability of alveolar macrophages to recognize
and/or clear particles of this size, resulting in a particle build up,
chronic inflammation, fibrosis, and tumor-genesis. However, many
studies have not shown a correlation between nanoparticles and
inflammation (Card, et al, 2008). Many studies also track whether
the particles translocate from the pulmonary system into systemic circulation. One of the studies reported to date indicate
that inhaled 99mtechnetium-labeled carbon nanoparticles, which
are man-made, are not detected outside of the lungs in significant
quantities after inhalation. However, as mentioned to by Mills et
al., these findings do not indicate that other nanoparticles will behave in the same manner, nor do they rule out the possibility that
nanoparticles may interact with and influence the vascular system
in the lungs. Moreover, the studies conducted to date have used a
single inhalation exposure protocol, and it is possible that repeated exposures may result in greater pulmonary accumulation and
transfer of significant quantities of nanoparticles to the circulation
(Mills, et al. 2006).
Fibrosis is a condition that many researchers believe is caused by
nanoparticle exposure. Many experiments were done using animals
to test the effects of primarily carbon nanotubes, carbon black,
fullerenes, silica, and metal-based nanoparticles including titanium
dioxide, silver, and nickel. Though it is known that the pathogenic
mechanisms underlying animal models of lung fibrosis and human
lung fibrosis are not necessarily the same, increased collagen deposits and structural deviations to the lungs can result in changed
respiratory mechanics that are common features of both. Fibrosis
in animal models is defined by increased collagen content and/or
histopathological evidence of structural alterations to the lung that
are consistent with fibrosis (Card, et al, 2008). It was found that
the type of carbon nanotubes, their length, and the way specific
fibers interact, all have varying effects on pulmonary inflammation
and fibrosis. Studies have found that the longer the nanotube fiber
length, the greater the toxicity, and the more likely it is to cause
fibrosis and cancer (Donaldson, et al. 2006).

Toxicity of Nanoparticle

Effects on Blood and Cardiovascular System
In a study by Radomski, et al, (2005) the effects of various
nanoparticles on platelet function were studied. In vitro studies
were done using human blood samples, and then in vivo studies
were done in rats to confirm the effects of platelet- aggregation found in the human blood. Engineered nanoparticles were
found to cause activation and aggregation of human platelets.
The efficacy of the nanoparticles in blood aggregation in vitro
was matched by the same results in the rats. Treatment with
nanoparticles caused rat vascular thrombosis. The data shows
that not all nanomaterials act similar in this test, and that surface area is not the only factor playing a role here. The data also
validates the idea that mainly cationic species have an effect on
blood clotting. Interestingly, this was the first study that allows
bridging of data, since a PM10 sample (SRM1648) was included in
the test-series, in combination with nanoparticles.The PM sample
actually showed a lower effect on platelet aggregation compared
to the carbon nanotubes (Radomski, Jurasz et al 2005). Another
study shows that repeated exposure to PM10’s causes a systemic
inflammatory response, including bone marrow stimulation, and
is related to the progression of atherosclerosis in the coronary
arteries and aorta (Suwa, et al. 2002).

Uptake and Effects of Nanoparticles in The Brain
Nanoparticles can gain access to the brain by two different
mechanisms. (1) Trans-synaptic transport after inhalation through
the olfactory epithelium. (2) Uptake through the blood-brain
barrier. The first pathway has been studied primarily with model
particles such as carbon, Au and MnO2 in experimental inhalation models in rats (Oberdörster et al 2004; Oberdörster,
Oberdörster et al 2005). The pathway via the BBB has been the
topic of research for a while, especially for drug delivery. Studies
suggest that the physiological barrier may hinder the distribution
of some proteins and viral particles after trans-vascular delivery
to the brain, suggesting that the healthy BBB contains defense
mechanisms protecting it from blood-borne nanoparticle exposure. When nanoparticles with different surface characteristics
were evaluated, neutral nanoparticles and low concentrations
of anionic nanoparticles were found to have no effect on the
BBB, whereas high concentrations of anionic nanoparticles and
cationic nanoparticles were toxic for the BBB (Nel et al 2006).
Fullerenes and C60 nanoparticles have been shown to induce
the production of reactive oxygen species, oxidative stress, and
rapid brain lipid peroxidation in marine species. Because of all the
negative effects on the brain by nanoparticles, further tests would
need to be done before using fullerenes and C60 for human and
industrial use (Oberdorster 2004).

Conclusion
Although there is a considerable amount of data on the toxicity
of nanoparticles, this data is mainly based on a small sampling

and the assumption that a lot of effects by particulate matter
are driven by the ultrafine particle fraction in it (Oberdörtster,
Oberdörster et al 2005). This small sampling doesn’t really give
enough information to adequately determine the potential hazards. Although hazard identification is the general approach for
safety evaluation of healthcare products, it is recommended to
add testing driven by the anticipated application and classification
by risk. Some engineered nanoparticles that are airborne will
pose inhalation and cardiovascular hazards, while cosmetics with
nanoparticles provide dermal exposures. Each nanoparticle formulation should be tested on a case-by-case basis in the requisite
ways focusing on their method of entry. In this respect the potential adverse effects of empty particles should also be considered.
In developing testing procedures and protocols a number of basic
issues need to be considered:
1) It needs to be determined whether noticed effects are caused
only by nanoparticles, or are the adverse effects caused by something else and only aggravated by nanoparticles. It is clear from
research that both PM and ultrafine particles can cause inflammation, cancer, etc., but these new and smaller nanoparticles may
cause different effects.
2) Most of the conclusions drawn about nanoparticles are based
on correlations made between the behavior of ultrafine particles
and PM’s to that of nanoparticles. The question is how much of
a correlation is permitted to be drawn, how many assumptions
can be made, as manufactured nanoparticles and ultrafine/ PM
particles are not identical.
3) The scientific world is dealing with a increasingly growing number of nanomaterials. All have the potential to create a new toxic
effect that has never been studied before.The current testing and
classification system for nanoparticles does not seem sufficient
to fully identify and quantify the toxicological effects of these new
nanoparticles.
For years pharmaceutical sciences have been using nanoparticles
to reduce toxicity and the side effects of drugs. Up to recently it
was not realized that these drug carrier systems themselves may
cause risks to the patient.The type of hazards that are introduced
by using nanoparticles for drug delivery are beyond what is posed
by conventional hazards imposed by chemicals. However, as of
current data, the scientific example for the possible toxic and adverse reactivity of nanoparticles is lacking and we have little understanding of the basics of the interaction of nanoparticles with
living cells, organs and organisms. A conceptual understanding of
biological responses to nanomaterials is needed in order to develop and apply safe nanomaterials in drug delivery in the future.
Furthermore, a close partnership between those working in drug
delivery and those working in particle toxicology is necessary for
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the exchange of concepts, methods and to establish a common
system for identifying the potential dangers of nanoparticles.
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